Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

NCT05768490 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

232

Enrollment

OTHER

Sponsor class

Conditions

Brain Metastases
Radiotherapy
EGFR Activating Mutation

Interventions

RADIATION: brain radiotherapy
DRUG: Almonertinib

Sponsor

Sun Yat-sen University